Form 8-K Pacira Pharmaceuticals, For: Apr 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
BofA/Merrill Lynch Upgrades Pacira Pharmaceuticals (PCRX) to Neutral (Earlier)
July 31, 2015 9:48 AM EDTBofA/Merrill Lynch earlier upgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Underperform to Neutral with a price target of $69.00 (from $70.00).
For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.
Shares of Pacira Pharmaceuticals closed at $61.80 yesterday.
... MorePacira Pharma (PCRX) Misses Q2 EPS by 1c
July 30, 2015 8:17 AM EDTPacira Pharma (NASDAQ: PCRX) reported Q2 EPS of $0.23, $0.01 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $59.1 million versus the consensus estimate of $62.97 million.
For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.
... More